<SEC-DOCUMENT>0001437749-22-029603-index.html : 20221222 <SEC-HEADER>0001437749-22-029603.hdr.sgml : 20221222 <ACCEPTANCE-DATETIME>20221222161907 ACCESSION NUMBER: 0001437749-22-029603 CONFORMED SUBMISSION TYPE: S-8 PUBLIC DOCUMENT COUNT: 6 REFERENCES 429: 333-198716 REFERENCES 429: 333-228960 REFERENCES 429: 333-250078 FILED AS OF DATE: 20221222 DATE AS OF CHANGE: 20221222 EFFECTIVENESS DATE: 20221222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NAVIDEA BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000810509 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 311080091 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-8 SEC ACT: 1933 Act SEC FILE NUMBER: 333-268956 FILM NUMBER: 221482205 BUSINESS ADDRESS: STREET 1: 4995 BRADENTON AVENUE STREET 2: SUITE 240 CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147937500 MAIL ADDRESS: STREET 1: 4995 BRADENTON AVENUE STREET 2: SUITE 240 CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: NEOPROBE CORP DATE OF NAME CHANGE: 19940714 </SEC-HEADER> <DOCUMENT> <TYPE>S-8 <SEQUENCE>1 <FILENAME>navb20221221_s8.htm <DESCRIPTION>FORM S-8 <TEXT> Document 1 - file: navb20221221_s8.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-5.1 <SEQUENCE>2 <FILENAME>ex_458445.htm <DESCRIPTION>EXHIBIT 5.1 <TEXT> Document 2 - file: ex_458445.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-10.1 <SEQUENCE>3 <FILENAME>ex_458446.htm <DESCRIPTION>EXHIBIT 10.1 <TEXT> Document 3 - file: ex_458446.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-23.2 <SEQUENCE>4 <FILENAME>ex_458468.htm <DESCRIPTION>EXHIBIT 23.2 <TEXT> Document 4 - file: ex_458468.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-FILING FEES <SEQUENCE>5 <FILENAME>ex_458447.htm <DESCRIPTION>EXHIBIT FILING FEES <TEXT> Document 5 - file: ex_458447.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>ex_458445img001.jpg <TEXT> Document 6 - file: ex_458445img001.jpg
</DOCUMENT> </SEC-DOCUMENT>